Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940154 · ClinicalTrials.gov registry record · Phase 2
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
A Phase 2 study of COPD Acute Exacerbation, sponsored by Connect Biopharm.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT06940154: Recruiting Phase 2 study of COPD Acute Exacerbation, sponsored by Connect Biopharm.
NCT06940154 is a Phase 2 study of COPD Acute Exacerbation that is actively recruiting participants, run by Connect Biopharm. The registered enrollment target is 160 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06940154, a Phase 2 study of COPD Acute Exacerbation, is actively recruiting participants, sponsored by Connect Biopharm.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Primary Outcome
Treatment failure is defined as death due to any cause, (re)admission to a hospital for COPD, ED (re)visit or unscheduled medical visit for worsening of COPD symptoms, or the necessity to intensify pharmacologic treatment (including second course of systemic steroids for COPD exacerbation) within 28 days after randomization.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Rademikibart in prefilled syringe
- DRUG Matching placebo in prefilled syringe
Study Locations (20)
Florida
- Synergy Healthcare - Bradenton
- Columbus Clinical Services, LLC - Miami
- Pharmax Research of South Florida, Inc. - Miami
- Health Synergy Clinical Research, LLC - West Palm Beach
Texas
- Inquest Clinical Research - Baytown
- Premier Pulmonary Critical Care and Sleep Medicine - Denison
- DCT- McAllen Primary Care Research, LLC dba Discovery Clinical Trials - McAllen
Georgia
- Primeway Clinical Research Group - Fayetteville
- Pivotal Research Solutions - Stonecrest
Buenos Aires
- CEMER - Centro Medico de Enfermedades Respiratorias - Florida
- Centro de Investigaciones Médicas Mar del Plata - Mar del Plata
Alabama
- University of Alabama at Birmingham Lung Health Center - Birmingham
California
- Amicis Research Center - Valencia
Colorado
- National Jewish Health - Denver
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT06940154 shows while recruiting
NCT06940154 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 1 condition, with COPD Acute Exacerbation appearing as the primary indexed condition, and to 2 interventions - of which Rademikibart in prefilled syringe is the first listed.
NCT06940154 names 20 study sites across 13 states, led by Florida, Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT06940154 about?
NCT06940154 is a clinical study titled "Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)". This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
What is the current status of trial NCT06940154?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-08-12. Estimated completion is 2026-05.
What conditions does trial NCT06940154 study?
This clinical trial studies the following conditions: COPD Acute Exacerbation.
What interventions are being tested in trial NCT06940154?
The interventions under investigation include: Rademikibart in prefilled syringe (COMBINATION_PRODUCT), Matching placebo in prefilled syringe (DRUG).
Who is sponsoring clinical trial NCT06940154?
This trial is sponsored by Connect Biopharm, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940154 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06940154's enrollment target sits among peer trials
160 422nd of 2000 higher than 1,560 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI